{"id":"W4410592778","doi":"10.1016/j.annonc.2025.04.006","title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"Unicancer; Grifols; Ipsen; Japanese Society of Medical Oncology; PharmaMar; European Society for Medical Oncology; Amgen; Koninklijke Nederlandse Akademie van Wetenschappen; Relay Therapeutics; Seagen; Genentech; Veracyte; Astellas Pharma; Fondazione Beretta; Mersana Therapeutics; Medical Research Council; Les Laboratories Pierre Fabre; Celldex Therapeutics; Advanced Accelerator Applications; Regeneron Pharmaceuticals; Natera; AstraZeneca; Associazione Italiana di Oncologia Medica; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; NeraCare; World Health Organization; Sanofi; Pfizer","keywords":"Medicine; Identification (biology); Scale (ratio); Medical physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309294,0.0001458869,0.001163227,0.000285727,0.0000513032,0.000008621305,0.0003724685,0.0003904573,0.0005660629],"category_scores_gemma":[0.0004638432,0.0001721708,0.0003479054,0.0002136323,0.000292378,0.0001964571,0.000138315,0.0002236499,0.0002397179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004447169,"about_ca_system_score_gemma":0.0001788837,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007156992,"about_ca_topic_score_gemma":0.00019514,"domain_scores_codex":[0.9976199,0.00002567269,0.0016372,0.0003701262,0.00002889784,0.0003182104],"domain_scores_gemma":[0.9980646,0.0002847216,0.0009712271,0.0003914532,0.0001912306,0.00009675066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005954021,0.000908001,0.57964,0.0001136474,0.000276675,0.000005030723,0.0002250579,0.0001184465,0.00003302132,0.2404493,0.06260647,0.1150289],"study_design_scores_gemma":[0.00131736,0.0009489324,0.4014904,0.00004058109,0.00001562429,8.893724e-7,0.00004785701,0.0001006229,0.001014965,0.05267709,0.542187,0.0001586987],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7237756,0.001775211,0.0001715451,0.003628223,0.00116074,0.0001354526,0.0001427914,0.0000128652,0.2691976],"genre_scores_gemma":[0.9903123,0.003261246,0.0007900766,0.002503582,0.0001532545,0.000008952765,0.00001236709,0.00001340156,0.002944821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4795805,"threshold_uncertainty_score":0.7020919,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1205150739325094,"score_gpt":0.401125847362559,"score_spread":0.2806107734300495,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}